Compare BIO-TECHNE Corp (TECH) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs UnitedHealth Group Inc — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while UnitedHealth Group Inc trades at $402.37 (market cap $371.19B). The key difference: UnitedHealth Group Inc is far larger — about 33× BIO-TECHNE Corp's market cap, and UnitedHealth Group Inc pays the higher dividend (2.27%). Which is the better fit depends on your goals.
| TECH | UNH | |
|---|---|---|
Market Cap | $11.24B | $371.19B |
Sector | Health | Health |
52-Week High | $72.29 | $436.35 |
52-Week Low | $43.31 | $259.02 |
Enterprise Value | $11.32B | $417.88B |
Dividend Yield | 0.44% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
UnitedHealth Group (UNH) trades at $402.19, down 1.2% in the last session, with a bearish technical signal but strong analyst support. The company reported revenue of $447.57B in 2025, with net income of $12.06B, and has consistently beaten EPS estimates in recent quarters. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns via dividends and buybacks.
Outlook remains positive due to aging demographics and Medicare growth, though regulatory risks and margin pressure present challenges. With 82.7% of analysts rating it a Buy and a consensus price target of $476.50, the stock offers upside potential, balanced by litigation and competitive threats in the managed care sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
